Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has announced promising results from a clinical study on dogs with osteoarthritis using Piclidenoson, conducted by their partner Vetbiolix. This success
Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma has announced promising results from a clinical study on dogs with osteoarthritis using Piclidenoson, conducted by their partner Vetbiolix. This success
Can-Fite BioPharma (CANF) announced that its veterinary partner Vetbiolix reported positive final results from the osteoarthritis multicenter clinical study in dogs treated with Piclidenoson. Vetbiolix, Can-Fite’s veterinary commercialization partner, which
Can-Fite BioPharma (CANF) has released an update. Can-Fite BioPharma Ltd., a biotech firm targeting oncological and inflammatory diseases, announced that its drug Namodenoson received Orphan Drug Designation from the FDA
המעמד המיוחד הזה כתרופת יתום אומר ש, אם תאושר, Namodenoson עשויה להיות היחידה מסוגה שתימכר למשך שבע שנים, והיא גם מגיעה עם מגוון יתרונות ויתרונות רגולטוריים שונים.
Can-Fite BioPharma announced the Company’s oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration, FDA, for the indication of pancreatic cancer, one